Search
Zymeworks Inc
ZYMEAdd to Watchlist
26.240USD
-0.230-0.87%
Close 11-13 16:00（ET）
1.85BMarket Cap
LossP/E TTM
About Zymeworks Inc Company
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Zymeworks Inc Profile
Ticker SymbolZYME
Company nameZymeworks Inc
IPO dateJun 24, 2019
CEOGalbraith (Kenneth H)
Number of employees280
Security typeOrdinary Share
Fiscal year-endJun 24
Address108 Patriot Drive, Suite A
CityMIDDLETOWN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19709
Phone13022748744
Websitehttps://www.zymeworks.com/
Ticker SymbolZYME
IPO dateJun 24, 2019
CEOGalbraith (Kenneth H)
Company Executives of Zymeworks Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Mark Hollywood
Mr. Mark Hollywood
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
133.85K
+0.70%
Mr. Gregory A. (Greg) Ciongoli
Mr. Gregory A. (Greg) Ciongoli
Independent Director
Independent Director
--
--
Ms. Suzanne Monahan
Ms. Suzanne Monahan
Senior Vice President, General Manager - Theravance Biopharma
Senior Vice President, General Manager - Theravance Biopharma
--
--
Ms. Kristin Stafford
Ms. Kristin Stafford
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Lindsey Foulkes
Dr. Lindsey Foulkes
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
--
--
Ms. Bijal Desai
Ms. Bijal Desai
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Ms. Laura O'Connor
Ms. Laura O'Connor
Senior Vice President, Chief Human Resources Officer
Senior Vice President, Chief Human Resources Officer
--
--
Dr. Sabeen Mekan
Dr. Sabeen Mekan
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
--
--
Mr. Brian N. Cherry
Mr. Brian N. Cherry
Director
Director
--
--
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Mark Hollywood
Mr. Mark Hollywood
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
133.85K
+0.70%
Mr. Gregory A. (Greg) Ciongoli
Mr. Gregory A. (Greg) Ciongoli
Independent Director
Independent Director
--
--
Ms. Suzanne Monahan
Ms. Suzanne Monahan
Senior Vice President, General Manager - Theravance Biopharma
Senior Vice President, General Manager - Theravance Biopharma
--
--
Ms. Kristin Stafford
Ms. Kristin Stafford
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Dr. Lindsey Foulkes
Dr. Lindsey Foulkes
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
--
--
Ms. Bijal Desai
Ms. Bijal Desai
Senior Vice President - Finance
Senior Vice President - Finance
--
--
FAQs
Who are the top five shareholders of Zymeworks Inc?
The top five shareholders of Zymeworks Inc are: Mr. Mark Hollywood